Accueil du site > European research and international cooperation > News




Rechercher

Sur ce site

Sur le Web du CNRS


Creation of two new International Associated Laboratories (LIA) in biological sciences, one in Belgium and one in Switzerland, both with teams from Lille

6 janvier 2017

In Switzerland, three teams, which have been working together for more than 15 years, are taking part in the LIA DIAGENIL, one team from a joint laboratory between the CNRS and Lille 2 University - Health and Law, and two other teams from the University of Lausanne.
The LIA is coordinated by Prof. Philippe Froguel, Director of the “Integrative Genomics and modeling of Metabolic Diseases” laboratory in Lille, and by Prof. Gérard Waeber, head of the Service of Internal Medicine in the Vaudois-University Hospital of Lausanne.
The LIA DIAGENIL scientific program will make it possible to identify and better to determine the genetic influence and the role of non-coding RNA on the development of diabetes and associated diseases, based on the Swiss cross-sectional population cohort “CoLaus” study.

In Belgium, the LIA GLYCOLAB4CDG institutionalizes a 10-year-old partnership between the CNRS, Lille 1 University of Sciences and Technology, and the Katholieke Universiteit Leuven (KU Leuven). It is co-funded by the Research Foundation – Flanders (FWO).
This LIA is based on the synergism and combination of complementary expertise in glycobiology and molecule and genome genetics from two laboratories : the team in Lille working on “Molecular mechanisms of N-glycosylation and associated diseases”, headed by Dr. François Foulquier, from the “Structural and Functional Glycobiology Unit” on one hand, and the Laboratory for Molecular Diagnosis – Center for Human Genetics of KU Leuven, headed by Prof. Gert Matthijs, on the other hand. It makes the most of the discovery of new genetic deficiencies for the discovery of precise molecular and cellular mechanisms of glycosylation, and for the screening and characterization of patients suffering from congenital disorders of glycosylation. In fine, those discoveries will lead to medical advances in terms of therapy and cure of patients.